All In Biotech

NDA 206439 · Abbvie

Namzaric

Donepezil Hydrochloride, Memantine Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Jul 18, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Dec 23, 2014

Approved uses

2

Original approval plus efficacy supplements

Registered trials

332

55 Phase 3, 12 recruiting

FAERS reports

608

261 serious, 72 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 6, 2026.

NAMZARIC is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. NAMZARIC is a combination of memantine hydrochloride, an NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor, indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. ( 1 )

Mechanism: NAMZARIC capsules contain two approved medications: memantine hydrochloride and donepezil hydrochloride. Each of those medications is postulated to have a different mechanism in Alzheimer’s disease. Memantine Persistent activation of central nervous system NMDA receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer’s disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open channel) NMDA receptor antagonist which binds preferentially to the NMDA...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • NAMZARIC · DONEPEZIL HYDROCHLORIDE 10MG; MEMANTINE HYDROCHLORIDE 28MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • NAMZARIC · DONEPEZIL HYDROCHLORIDE 10MG; MEMANTINE HYDROCHLORIDE 7MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • NAMZARIC · DONEPEZIL HYDROCHLORIDE 10MG; MEMANTINE HYDROCHLORIDE 14MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • NAMZARIC · DONEPEZIL HYDROCHLORIDE 10MG; MEMANTINE HYDROCHLORIDE 21MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Donepezil" as an intervention, any sponsor and status, largest first.

All 332 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death58
  • dizziness58
  • confusional state48
  • drug ineffective42
  • fall42
  • hallucination38
  • fatigue37
  • diarrhoea36
  • nausea33
  • vomiting32
  • off label use26
  • malaise23

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20159
201650
2017156
201876
201999
202073
202143
202232
202323
202423
202516
20268

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Namzaric (Memantine HCl/Donepezil HCl)

2024 spending

$89.6M

Beneficiaries

18,217

129,758 claims

Per beneficiary

$4,919

$19.42 per unit

View as table
YearSpending
2020$204,698,827
2021$168,489,872
2022$134,151,991
2023$107,814,107
2024$89,617,222

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 799 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.